|
Mar 22
|
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
|
|
Mar 20
|
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
|
|
Jan 30
|
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
|
|
Jan 26
|
Quest Diagnostics (DGX) Advances in Cancer Research With New Deal
|
|
Jan 9
|
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
|
|
Jan 5
|
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 221% Above Its Share Price
|
|
Dec 21
|
Genetic Testing Pioneer Myriad Genetics' Evolution Draws Analyst Attention Amid New Product(s) Anticipation
|
|
Dec 21
|
Myriad Genetics' (MYGN) New Platform to Advance Cancer Care
|
|
Dec 21
|
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance
|
|
Dec 20
|
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
|
|
Dec 6
|
Why Is Myriad (MYGN) Up 3% Since Last Earnings Report?
|
|
Nov 20
|
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
|
|
Nov 20
|
Myriad Genetics (MYGN) Expands Pharma Services With New Pact
|
|
Nov 16
|
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
|
|
Nov 9
|
Myriad Genetics Announces Pricing of Upsized Offering of Common Stock
|
|
Nov 8
|
Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock
|
|
Nov 8
|
Myriad Genetics (NASDAQ:MYGN) adds US$182m to market cap in the past 7 days, though investors from five years ago are still down 41%
|
|
Nov 7
|
Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2023 Earnings Call Transcript
|
|
Nov 7
|
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q3
|
|
Nov 7
|
Myriad (MYGN) Reports Q3 Earnings: What Key Metrics Have to Say
|